| Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals T Kustin, N Harel, U Finkel, S Perchik, S Harari, M Tahor, I Caspi, R Levy, ... Nature medicine 27 (8), 1379-1384, 2021 | 396 | 2021 |
| Developing a COVID-19 mortality risk prediction model when individual-level data are not available N Barda, D Riesel, A Akriv, J Levy, U Finkel, G Yona, D Greenfeld, ... Nature communications 11 (1), 4439, 2020 | 133 | 2020 |
| Short-term adverse events after the third dose of the BNT162b2 mRNA COVID-19 vaccine in adults 60 years or older O Auster, U Finkel, N Dagan, N Barda, A Laufer, RD Balicer, ... JAMA network open 5 (4), e227657-e227657, 2022 | 17 | 2022 |
| Performing risk stratification for COVID-19 when individual level data is not available–the experience of a large healthcare organization N Barda, D Riesel, A Akriv, J Levi, U Finkel, G Yona, D Greenfeld, ... medRxiv, 2020.04. 23.20076976, 2020 | 13 | 2020 |
| Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals. medRxiv [Preprint]. April 9, 2021 T Kustin, N Harel, U Finkel | 6 | |
| IMAJ| volume 24 M Mahanaimy, U Finkel, N Barda, E Rottman, R Balicer, AB Senderey, ... Journal 5, May, 310-316, 2022 | 2 | 2022 |
| COVID-19 関連追加 (2021 年 6 月 23 日-2) ワクチンブレイクスルー感染についてその 3 [BNT162b2-mRNA ワクチン接種者では, SARS-CoV-2 VOC のブレイクスルー率が増加する] T Kustin, N Harel, U Finkel | | |
